Related references
Note: Only part of the references are listed.A Comparative Study of Carvedilol Versus Metoprolol Initiation and 1-Year Mortality Among Individuals Receiving Maintenance Hemodialysis
Magdalene M. Assimon et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2018)
β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial
Alvin Tieu et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Beta blockers in patients with end-stage renal diseaseEvidence-based recommendations
Matthew A. Weir et al.
SEMINARS IN DIALYSIS (2018)
Carvedilol and Cardiac Biomarkers in Dialysis Patients: Secondary Analysis of a Randomized Controlled Trial
Matthew A. Roberts et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2017)
Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure
Hanna Froehlich et al.
CLINICAL RESEARCH IN CARDIOLOGY (2017)
Sensitivity Analysis in Observational Research: Introducing the E-Value
Tyler J. VanderWeele et al.
ANNALS OF INTERNAL MEDICINE (2017)
The β-Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled Trial
Matthew A. Roberts et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2016)
Mechanisms and Treatment of Intradialytic Hypertension
Peter Noel Van Buren et al.
BLOOD PURIFICATION (2016)
Effectiveness comparison of cardio-selective to non-selective β-blockers and their association with mortality and morbidity in end-stage renal disease: a retrospective cohort study
Theresa I. Shireman et al.
BMC CARDIOVASCULAR DISORDERS (2016)
Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease
Vincent Yi-Fong Su et al.
MEDICINE (2016)
Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort
Chao-Hsiun Tang et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2016)
Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database
Cheng-Yang Hsieh et al.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2015)
β-Blockers in Dialysis Patients: A Nephrocardiology Perspective
Gautam R. Shroff et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
β-Blocker Dialyzability and Mortality in Older Patients Receiving Hemodialysis
Matthew A. Weir et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs
T. Stuermer et al.
JOURNAL OF INTERNAL MEDICINE (2014)
Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial
Rajiv Agarwal et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2014)
On the joint use of propensity and prognostic scores in estimation of the average treatment effect on the treated: a simulation study
Finbarr P. Leacy et al.
STATISTICS IN MEDICINE (2014)
Prespecified Falsification End Points Can They Validate True Observational Associations?
Vinay Prasad et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Chronic kidney disease: global dimension and perspectives
Vivekanand Jha et al.
LANCET (2013)
The performance of different propensity score methods for estimating marginal hazard ratios
Peter C. Austin
STATISTICS IN MEDICINE (2013)
Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis
Saurav Chatterjee et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
Utilization and Costs of Cardiovascular Disease Medications in Dialysis Patients in Medicare Part D
Diane L. Frankenfield et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2012)
Interdialytic ambulatory blood pressure in patients with intradialytic hypertension
Peter N. Van Buren et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2012)
Beta-blockers and cardiovascular outcomes in dialysis patients: a cohort study in Ontario, Canada
Abhijat Kitchlu et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2012)
Carvedilol: a third-generation β-blocker should be a first-choice β-blocker
James J. DiNicolantonio et al.
EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2012)
Population-Based Analysis of Class Effect of β Blockers in Heart Failure
Darius Lucian Lazarus et al.
AMERICAN JOURNAL OF CARDIOLOGY (2011)
Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan
Ching-Lan Cheng et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2011)
Negative Controls A Tool for Detecting Confounding and Bias in Observational Studies
Marc Lipsitch et al.
EPIDEMIOLOGY (2010)
HFSA 2010 Comprehensive Heart Failure Practice Guideline
Heart Failure Society of America
JOURNAL OF CARDIAC FAILURE (2010)
Blood pressure in chronic kidney disease stage 5D-report from a Kidney Disease: Improving Global Outcomes controversies conference
Nathan W. Levin et al.
KIDNEY INTERNATIONAL (2010)
Beta blockers in the management of chronic kidney disease
G. L. Bakris et al.
KIDNEY INTERNATIONAL (2006)
Treatment of hypertension in dialysed patients
LN Kiss et al.
JOURNAL OF HYPERTENSION (2005)
β-Blocker use in long-term dialysis patients -: Association with hospitalized heart failure and mortality
KC Abbott et al.
ARCHIVES OF INTERNAL MEDICINE (2004)
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension - A randomized controlled trial
GL Bakris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study
RN Foley et al.
KIDNEY INTERNATIONAL (2002)
Dilated cardiomyopathy in dialysis patients - Beneficial effects of carvedilol: A double-blind, placebo-controlled trial
G Cice et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2001)